Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: Effects of Alzheimer's disease and gender

Biological Psychiatry

Volumn 40, Issue 1, 1996, Pages 61-68

  Peskind, Elaine R ^a,b,d   Raskind, Murray A ^a,b   Wingerson, Dane ^a,b   Pascualy, Marcella ^a,b   Thal, Leon J ^c   Dobie, Dorcas J ^a,b   Wilkinson, Charles W ^a,b  

^a Education   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Beta endorphin; Corticotropin; Cortisol; Gender; Physostigmine

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PHYSOSTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL;

EID: 0029953105     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00318-5     Document Type: Article

References (42)

1. Bird TD, Stranahan S, Sumi SM, Raskind MA (1983): Alzheimer's disease: Choline acetyl transferase activity in brain tissue from clinical and pathologic subgroups. Ann Neurol 14:284-293.
2. Bodnoff SR, Humphreys AG, Lehman JC, Diamond DM, Rose GM, Meaney MJ (1995): Enduring effects of chronic corticosterone treatment in spatial learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. J Neurosci 15:61-69.
3. Davies P, Maloney AJF (1976): Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet ii:1043.
4. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, Johns CA, Horvath TB (1986): Cortisol and Alzheimer's disease: I. Basal studies. Am J Psychiatry 143:300-305.
5. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Dooly RS (1992): A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327:1253-1259.
6. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RAE, Chui HC, Knopman DS, Reeder TM, Shetter AG, Senter HJ, Markesbery WR, and the Intraventricular Bethanecol Study Group (1992): Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Ann Neurol 32:625-632.
7. Dixon WJ (1987): BMDP Statistical Software Manual. Berkeley, CA: University of California Press, p 52.
8. Dorsa DM, Bottemiller LA (1983): Vasopressin-like peptides in the rat brain: Immunologic and chromatrographic behavior and their response to water deprivation. Regul Pept 6:393-403.
9. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J (1992): A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523-2529.
10. Flynn DD, Weinstein DA, Mash DC (1991): Loss of high affinity agonist binding to muscarin receptor in Alzheimer's disease: Implications for failure of cholinergic replacement therapies. Ann Neurol 29:256-262.
11. Folstein MF, Folstein SE, McHugh PR (1975): Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
12. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary P, Snowden JS, Wilcock GK (1985): Neurochemical studies of early-onset Alzheimer's disease. N Engl J Med 313:7-11.
13. Gottfries CG, Balldin J, Blennow K, Bråne G, Karlsson I, Regland B, Wallin A (1994): Regulation of the hypothalamic-pituitary-adrenal axis in dementia disorders. Ann NY Acad Sci 746:336-344.
14. Greenspan SL, Rowe JW, Maitland LA, McAloon-Dyke M, Elahi D (1993): The pituitary-adrenal glucocorticoid response is altered by gender and disease. J Gerontol 48:M72-M77.
15. Greenwald BS, Mathe AA, Mohs RC (1986): Cortisol and Alzheimer's disease: II. Dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry 143: 442-448.
16. Hasey G, Hanin I (1990): Plasma corticosterone is increased and correlated with brain acetylcholine in physostigmine-but not in neostigmine-treated rats. Psychoneuroendocrinology 15: 357-369.
17. Heuser IJ, Gotthardt U, Schweiger U, Schmider J, Lammers C-H, Dettling M, Holsboer F (1994): Age-associated changes of pituitary-adrenocortical hormone regulation in humans: Importance of gender. Neurobiol Aging 15:227-231.
18. Kjaer A, Knigge U, Flemming WB, Warben J (1992): Histamine- and stress-induced secretion of ACTH and β-endorphin: Involvement of corticotropin-releasing hormone and vasopressin. Neuroendocrinology 56:419-428.
19. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SD (1994): A 30 week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 271:985-998.
20. Landfield P, Baskin R, Pitler T (1981): Brain aging correlates: Retardation by hormonal-pharmacological treatments. Science 214:581-584.
21. Lewis DA, Sherman BA, Kathol RG (1984): Analysis of the specificity of physostigmine stimulation of adrenocorticotropin in man. J Clin Endocrinol Metab 58:570-573.
22. Maeda K, Tanimoto K, Terada T, Shintani T, Kakigi TA (1991): Elevated urinary free cortisol in patients with dementia. Neurobiol Aging 12:161-163.
23. Martignoni E, Petraglia F, Costa A, Bono G, Genazzini AR, Nappi G (1990): Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: Changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. Acta Neurol Scand 81:452-456.
24. Masugi T, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, Morimoto S, Kumahara Y, Saeki S, Nishide M (1989): High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type. Meth Find Exp Clin Pharmacol 11: 707-710.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis of Alzheimer's disease. Neurology 34:939-944.
26. Miller AH, Sastry G, Speranza AJ Jr, Lawlor BA, Mohs RC, Ryan TM, Gabriel SM, Serby M, Schmeidler J, Davis KL (1994): Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. Am J Psychiatry 151:267-270.
27. Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Veith RC, Dorsa DM, Murray S, Sikkema C, Galt SA, Wilkinson CW (1995): Enhanced hypothalamic pituitary adrenocortical axis responses to physostigmine in normal aging. J Gerontol 50A:M114-M120.
28. 1 agonist methoxamine in man. Neuroendocrinology 55:361-366.
29. Raskind MA, Peskind E, Rivard MF, Veith R, Barnes R (1982): Dexamethasone suppression test and cortical circadian rhythm in primary degenerative dementia. Am J Psychiatry 13:1468-1471.
30. Raskind MA, Peskind ER, Veith RC, Risse SC, Lampe TH, Borson S, Gumbrecht G, Dorsa DM (1989): Neuroendocrine responses to physostigmine in Alzheimer's disease. Arch Gen Psychiatry 46:535-540.
31. Raskind MA, Peskind ER, Veith RC, Wilkinson CW, Federighi D, Dorsa DM (1990): Differential effects of aging on neuroendocrine responses to physostigmine in normal men. J Clin Endocrinol Metab 70:1420-1425.
32. Resnick NM, Greenspan SL (1989): "Senile" osteoporosis reconsidered. JAMA 261:1025-1029.
33. Risch SC, Kalin NH, Janowsky DS, Cohen RM, Pickar D, Murphy DL (1983): Corelease of ACTH and β-endorphin immunoreactivity in human subjects in response to central cholinergic stimulation. Science 222:77-79.
34. Rolandi E, Gandolfo C, Franceschini R, Cataldi A, Garibaldi A, Barreca T (1992): Twenty-four-hour beta-endorphin secretory pattern in Alzheimer's disease. Neuropsychobiology 25:188-192.
35. Sapolsky RM, Krey LC, McEwen B (1985): Prolonged glucocorticoid exposure reduces hippocampal neuron number: Implications for aging. J Neurosci 5:1222-1227.
36. Sapolsky RM, Uno H, Rebert CS, Finch CE (1990): Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 10:2897-2902.
37. Spar JE, Gerner R (1982): Does the dexamethasone suppression test distinguish dementia from depression? Am J Psychiatry 139:238-240.
38. Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R (1994): Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci 14:5373-5380.
39. Weinberger DR, Gibson R, Coppola R, Jones DW, Molchan S, Sunderland T, Berman KF, Reba RC (1991): The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. Arch Neurol 48:169-176.
40. Whitehouse PJ, Price DL, Strable RG, Clark AW, Coyle JT, DeLong MR (1982): Alzheimer's disease: Loss of neurons in the basal forebrain. Science 215:1237-1239.
41. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, Kellar KJ (1986): Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371: 146-151.
42. Winker MA (1994): Tacrine for Alzheimer's disease: Which patient, what dose? JAMA 271:1023-1024.